Acute relapses represent transient neurological dysfunction driven by focal inflammatory activity within the central nervous system. Rapid intervention aims to shorten symptom duration, expedite ...

Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple ...

New research presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025) demonstrates that ocrelizumab provides superior control of ...

Research findings from Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2023 provide updates on MS diagnosis and treatment. Research presented at the Americas ...

Roche Holding AG said a multiple sclerosis drug showed it could work for most forms of the disease in two late-stage trials, cutting the number of relapses compared to another treatment over nearly ...

Multiple sclerosis (MS) is a condition that disrupts the information pathways that connect your brain and your body. From time to time, the symptoms of MS can unexpectedly worsen. When symptoms ...

Emerging science is shaking up what has been previously known about multiple sclerosis (MS), changing our understanding of the basic biology of the disease. For years, the classical picture of MS has ...